secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001746473-23-000072
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics reports Q3 net loss of $41.5M; positive bexotegrast PSC interim data
--------------------------------------------------------------------------------

- Net loss of $41.5M vs $30.6M in prior-year quarter; R&D expense $32.3M, G&A $15.3M.
- Cash, cash equivalents and short-term investments of $523.6M, funding operations into H2 2026.
- Positive 12-week data from Phase 2a INTEGRIS-PSC trial; 160 mg dose showed statistically significant reduction in ELF and PRO-C3 vs placebo.
- DSMB recommended INTEGRIS-PSC continue without modification; 320 mg data expected Q1 2024.
- Appointed Minnie Kuo as Chief Development Officer and Mishima Gerhart as Chief Regulatory Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647323000072/0001746473-23-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647323000072/plrx-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001746473-23-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer